Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Update

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 96,300 shares, an increase of 20.7% from the May 31st total of 79,800 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is currently 0.1 days.

Qualigen Therapeutics Stock Performance

Qualigen Therapeutics stock opened at $0.17 on Tuesday. Qualigen Therapeutics has a twelve month low of $0.14 and a twelve month high of $1.26. The company’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.39.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.